Offene Studie zur Bewertung der Sicherheit und Wirksamkeit von CABA-201 bei Patienten mit aktiver idiopathischer entzündlicher Myopathie
Eine offene Phase-1/2-Studie zur Bewertung der Sicherheit und Wirksamkeit autologer CD19-spezifischer chimärer Antigenrezeptor-T-Zellen (CABA-201) bei Patienten mit aktiver idiopathischer entzündlicher Myopathie
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Cabaletta Bio
- Telefonnummer: 4444 267-759-3100
- E-Mail: clinicaltrials@cabalettabio.com
Studienorte
-
-
-
Göttingen, Deutschland, 37075
- Noch keine Rekrutierung
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Kontakt:
- Dr. Jana Zschüntzsch
- E-Mail: j.zschuentzsch@med.uni-goettingen.de
-
Hauptermittler:
- Dr. Jana Zschüntzsch
-
-
-
-
-
Roma, Italien, 00165
- Rekrutierung
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Dr. Marco Becilli
- Telefonnummer: +39 0668592739
- E-Mail: marco.becilli@opbg.net
-
Hauptermittler:
- Professor Franco Locatelli
-
-
-
-
California
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- University of California Irvine - Accepting Adult Patients
-
Hauptermittler:
- Tahseen Mozaffar, MD
-
Kontakt:
- Alpha Clinic
- Telefonnummer: 949-824-3990
- E-Mail: alphaclinic@uci.edu
-
San Francisco, California, Vereinigte Staaten, 94158
- Rekrutierung
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Zilan Zheng
- Telefonnummer: 415-353-1301
- E-Mail: Zilan.Zheng@ucsf.edu
-
Hauptermittler:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80046
- Rekrutierung
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Hauptermittler:
- Dr. Kentaro Yomogida, MD
-
Kontakt:
- Callie Strini - Primary Clinical Research Coordinator
- Telefonnummer: 720-777-9845
- E-Mail: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic Florida - Accepting Adult Patients
-
Kontakt:
- Gabrielle Pariseau
- Telefonnummer: 904-953-5549
- E-Mail: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Rekrutierung
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Hauptermittler:
- Natalie Booth, DO
-
Kontakt:
- Laura Escobar
- Telefonnummer: 727-767-2946
- E-Mail: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30032
- Rekrutierung
- Emory University - Accepting Adult Patients
-
Kontakt:
- John Varghese
- E-Mail: john.varghese@emory.edu
-
Hauptermittler:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Vereinigte Staaten, 30029
- Rekrutierung
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Hauptermittler:
- Shanmuganathan Chandrakasan, MD
-
Kontakt:
- Judson Russell
- Telefonnummer: 404-785-7263
- E-Mail: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Hauptermittler:
- Dr. George Georges, MD
-
Kontakt:
- Kaitlin King
- Telefonnummer: 312-695-0990
- E-Mail: autoimmunesct@nm.org
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Hauptermittler:
- Dr. Iazsmin Ventura, MD
-
Kontakt:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Telefonnummer: 773-702-6619
- E-Mail: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Unterermittler:
- Dr. Cuoghi Edens, MD, FAAP
-
Kontakt:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- E-Mail: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Tyler Sorensen
- Telefonnummer: 312-277-6828
- E-Mail: tsorensen@luriechildrens.org
-
Hauptermittler:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Medical Center - Accepting Adult Patients
-
Kontakt:
- Samantha Colgan
- Telefonnummer: 913-945-9938
- E-Mail: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- Rekrutierung
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Kontakt:
- Julie Thompson
- Telefonnummer: 301-480-3191
- E-Mail: Julie.thompson@nih.gov
-
Hauptermittler:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Hauptermittler:
- Susan Prockop, MD
-
Kontakt:
- Kyle McBrearty
- Telefonnummer: 617-355-2780
- E-Mail: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48105
- Rekrutierung
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Abigail Whalen
- Telefonnummer: 734-615-4466
- E-Mail: abigaiwh@med.umich.edu
-
Hauptermittler:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55902
- Rekrutierung
- Mayo Clinic - Accepting Adult Patients
-
Kontakt:
- Bridget Neja
- Telefonnummer: 507-266-9150
- E-Mail: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Kontakt:
- Janvi Bhatia
- Telefonnummer: 212-774-2123
- E-Mail: bhatiaj@hss.edu
-
Hauptermittler:
- David R. Fernandez, MD, PhD
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Hauptermittler:
- Jae Park, MD
-
Kontakt:
- Atifah Osrat
- Telefonnummer: 646-608-2091
- E-Mail: osrata1@mskcc.org
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Emily Gillies
- Telefonnummer: 718-696-2402
- E-Mail: egillies@montefiore.org
-
Hauptermittler:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Hauptermittler:
- Saira Sheikh, MD
-
Kontakt:
- Leah Luizza
- E-Mail: leah.luizza@med.unc.edu
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Hauptermittler:
- Kaveh Ardalan, MD, MS
-
Kontakt:
- Lynn Rodgers, MS
- Telefonnummer: 919-668-2953
- E-Mail: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health & Science University - Accepting Adult Patients
-
Kontakt:
- Katie Lewis
- Telefonnummer: 503-908-9724
- E-Mail: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- CARTintake@chop.edu
- E-Mail: CARTintake@chop.edu
-
Hauptermittler:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15261
- Rekrutierung
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Kontakt:
- Carol Oriss
- E-Mail: orissca@upmc.edu
-
Hauptermittler:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Kontakt:
- Vibha Chauhan, PhD
- Telefonnummer: 412-692-7924
- E-Mail: Vibha.chauhan@chp.edu
-
Hauptermittler:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Kontakt:
- Tofi Soneye
- Telefonnummer: 817-883-4730
- E-Mail: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Hauptermittler:
- Samuel John, MD
-
Kontakt:
- Dr. Samuel John
- E-Mail: dtpteam@childrens.com
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Houston Methodist Hospital - Accepting Adult Patients
-
Kontakt:
- Amelia A. Nounes, MSN, RN, CCRP
- Telefonnummer: 346-356-3639
- E-Mail: aanounes@houstonmethodist.org
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Hauptermittler:
- Huifang (Linda) Lu, MD
-
Kontakt:
- Christina Amos Briggs, BSN, RN
- Telefonnummer: 713-563-5076
- E-Mail: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Rekrutierung
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Kontakt:
- Morgan Badgley - Research Coordinator
- Telefonnummer: 801-662-4812
- E-Mail: morgan.badgley@hsc.utah.edu
-
Hauptermittler:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Rekrutierung
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Kontakt:
- Dr. Susan Shenoi, MD, MS
- Telefonnummer: 206-987-2193
- E-Mail: susan.shenoi@SeattleChildrens.org
-
Hauptermittler:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Noch keine Rekrutierung
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Hauptermittler:
- Sara Sabbagh, DO
-
Kontakt:
- Erin Hammelev - Research Coordinator
- Telefonnummer: 414-337-7064
- E-Mail: ehammele@mcw.edu
-
-
-
-
-
London, Vereinigtes Königreich, WC1N 3BG
- Rekrutierung
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Dr. Pedro Machado, FRCP, PhD
- Telefonnummer: 020 3456 7890
- E-Mail: uclh.car-ttrials@nhs.net
-
Hauptermittler:
- Dr. Pedro Machado, FRCP, PhD
-
London, Vereinigtes Königreich, SE5 9RS
- Rekrutierung
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Rheumatology Research Team
- Telefonnummer: 0628 0207 848 0214
- E-Mail: Kch-tr.CRDresearch@nhs.net
-
Hauptermittler:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Vereinigtes Königreich, WC1N 3JH
- Rekrutierung
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Kontakt:
- Professor Despina Eleftheriou
- Telefonnummer: 020 7405 9200
- E-Mail: Despina.Eleftheriou@gosh.nhs.uk
-
Hauptermittler:
- Professor Despina Eleftheriou
-
Manchester, Vereinigtes Königreich, M13 9WL
- Rekrutierung
- Manchester Royal Infirmary - Accepting Adult Patients
-
Kontakt:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Telefonnummer: 01612765052
- E-Mail: Eleni.Tholouli@mft.nhs.uk
-
Hauptermittler:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Vereinigtes Königreich, M6 8HD
- Rekrutierung
- Salford Royal Hospital - Accepting Adult Patients
-
Kontakt:
- Michelle Beswick
- Telefonnummer: 07759 136787
- E-Mail: Rheumatology.Research@nca.nhs.uk
-
Hauptermittler:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere Namen:
|
|
Experimental: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere Namen:
|
|
Experimental: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Zeitfenster: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Zeitfenster: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Zeitfenster: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Zeitfenster: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Zeitfenster: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Zeitfenster: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Zeitfenster: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Zeitfenster: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Zeitfenster: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Zeitfenster: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienstuhl: Medical Director, Cabaletta Bio
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Myositis
- Dermatomyositis
- Autoimmunerkrankung
- Zelltherapie
- Juvenile Dermatomyositis
- CABA-201
- Anti-CD19-CAR-T-Therapie
- Idiopathische entzündliche Myopathie
- Anti-Synthetase-Syndrom
- Immunvermittelte nekrotisierende Myopathie
- Juvenile Polymyositis
- Juvenile idiopathische entzündliche Myopathie (JIIM)
- Juvenile Myositis
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Bewegungsapparates
- Erkrankungen des Nervensystems
- Muskelerkrankungen
- Neuromuskuläre Erkrankungen
- Bindegewebserkrankungen
- Erkrankungen des Immunsystems
- Hautkrankheiten
- Polymyositis
- Haut- und Bindegewebserkrankungen
- Autoimmunerkrankungen
- Dermatomyositis
- Myositis
- Organische Chemikalien
- Kohlenwasserstoffe
- Phosphoramid -Senf
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Phosphoramide
- Organophosphorverbindungen
- Cyclophosphamid
- Fludarabine
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CAB-201-002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .